Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme

Cancer Gene Therapy

Volumn 10, Issue 3, 2003, Pages 201-208

  Luzi, Ettore ^a,c   Papucci, Laura ^a   Schiavone, Nicola ^a   Donnini, Martino ^a   Lapucci, Andrea ^a   Tempestini, Alessio ^a   Witort, Ewa ^a   Nicolin, Angelo ^b   Capaccioli, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Biosensor Laboratory   (Italy)

Author keywords

Apoptosis; AU rich RNA destabilizing element (ARE); Bcl 2 overexpression; Gene therapy; Lymphoma; Modified hammerhead; Ribozyme

Indexed keywords

CELL EXTRACT; COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN BCL 2; RIBOZYME;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ANALYSIS; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAJI CELL; REGULATORY MECHANISM; RNA ANALYSIS;

APOPTOSIS; BASE SEQUENCE; BURKITT LYMPHOMA; CATALYTIC DOMAIN; CELL LINE, TUMOR; DOWN-REGULATION; GENES, SYNTHETIC; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; REGULATORY SEQUENCES, RIBONUCLEIC ACID; RNA, CATALYTIC; RNA, MESSENGER;

EID: 0037347131     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700556     Document Type: Article

References (31)

1. Birikh KR, Heaton PA, Eckstein F. The structure, function and application of the hammerhead ribozymes. Eur J Biochem. 1997;245:1-16.
2. Bramlage B, Luzi E, Eckstein F. Designing ribozymes for the inhibition of gene expression. Trends Biotechnol. 1998;16:434-438.
3. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNA for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47:19-28.
4. Chen-Levy Z, Nourse J, Cleary ML. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol. 1989;9:701-710.
5. Vaux D, Cory S, Adams JM. Bcl-2 gene promoters haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
6. Reed JC. Bcl-2 family proteins:regulators od apoptosis and chemioresistance in hematologic malignancies. Semin Hematol. 1997;34:9-19.
7. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000;18:1812-1823.
8. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutic: state of the art and future prospects. Blood. 1998;92:712-736.
9. Schiavone N, Rosini P, Quattrone A, et al. A conserved AU-rich element in the 3′ untraslated region of bcl-2 mRNA is endowed with destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J. 2000;14:174-184.
10. Wilson GM, Brewer G. Identification and characterization of proteins binding A + U-rich elements. Methods Enzymol. 1999;17:74-83.
11. Donnini M, Lapucci A, Papucci L, et al. Apoptosis is associated with modifications of bcl-2 mRNA AU-binding proteins. Biochem Biophys Res Comm. 2001;287:1063-1069.
12. Yang J-H, Usman N, Chartrand P, et al. Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain. Biochemistry. 1992;31:5005-5009.
13. Goodchild J. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation. Nucleic Acids Res. 1992;20:4607-4612.
14. Heidenreich O, Benseler F, Fahrenholz A, et al. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleosides and phosphorothioate. J Biol Chem. 1994;269:2131-2138.
15. Bramlage B, Luzi E, Eckstein F. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition og gene expression: site selection and inhibition in cell culture. Nucleic Acids Res. 2000;28:4059-4067.
16. Shimayama T, Nishikawa F, Nishikawa S, et al. Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages. Nucleic Acids Res. 1993;21:2605-2611.
17. Bevilacqua A, Ceriani MC, Schiavone N, et al. BCL-2 regulation targeting the AU-rich domain. Nucleosides, Nucleotides Nucleic Acids. 2000;19:1273-1279.
18. Quattrone A, Papucci L, Santini V, et al. Quantitation of bcl-2 oncogene in cultured lymphoma/leukemia cell lines and in primary leukemia b-cells by a highly sensitive RT-PCR method. Haematologica. 1995;80:495-504.
19. Zuker M, Stiegler P. Optimal computer folding of large RNA sequences using thermodynamic and auxiliary information. Nucleic Acids Res. 1981;9:133-148.
20. Julien T, Frankel B, Longo S, et al. Antisense-mediated inhibition of the Bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol. 2000;53:360-368.
21. Jansen B, Wacheck V, Heere-Ress E, et al. Chemosensitisation of malignant melanoma by BCL2 antisense theraoy. Lancet. 2000;356:1728-1733.
22. Uchida T, Gao JP, Wang C, et al. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice. Mol Urol. 2001;5:71-78.
23. Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin Oncol. 2001;28:67-70.
24. Konopleva M, Tari AM, Estrov Z, et al. Liposomal Bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine-arabinoside, and induce apoptosis independent of other antiapoptotic proteins. Blood. 2000;95:3929-3938.
25. Gibson S, Pellenz C, Hutchison RE, et al. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res. 2000;6:213-222.
26. Potter PM, McKenzie PP, Hussain N, et al. Construction of adenovirus for high level expression of small RNAs in mammalian cells. Mol Biotechnol. 2000;15:105-114.
27. Dorai T, Perlman H, Walsh K, et al. A recombinant defective adenoviralagent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2 expressing human prostate cancer cells. Int J Cancer. 1999;82:846-852.
28. Dorai T, Olson CA, Katz AE, et al. Development of a hammerhead ribozyme against bcl-21. Preliminary evalutation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate. 1997;32:246-258.
29. Scheid S, Heinzinger M, Waller CF, et al. Bcl-2 mRNA-targeted ribozymes:effects on programmed cell death in chronic myelogenous leukemia cell lines. Ann Hematol. 1998;76:117-125.
30. Webb A, Cunningham D, Cother F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 1997;349:1137-1141.
31. Wilson GM, Sutphen K, Chuang K, et al. Folding of A + U-rich RNA elements modulates AUF1 binding. J Biol Chem. 2001;276:8695-8704.